SEP 9·SEC EDGARLow
Patel Sanjiv sold $913K of RLAY
Patel Sanjiv (President and CEO) sold 48,199 shares of Relay Therapeutics, Inc. (RLAY) at $18.94 ($0.91M total) on 2026-09-08 under a Rule 10b5-1 trading plan.
StockNASDAQ · US · USDHealthcare · Biotechnology
$RLAY
Relay Therapeutics, Inc.
Price · $RLAYvia TradingView
AI sentiment · 7d0 articles
No enriched coverage for $RLAY in the last 7 days.
Insider · 30dAll trades →
- Buys
- — 0 txs
- Sells
- $117.9M 5 txs
Rahmer Peter1× · $90K
10b5-1 share of filings80%
Top stories · $RLAYMore →
AUG 31·investing.com
Top insider buys and sells from Friday’s market activity
On August 28, 2026, notable insider trading included Optimum Communications (OPTU) director Neil S. Subin buying $2.45M in shares, REGENXBIO (RGNX) director Gregory Austin Ciongoli purchasing $949K, and Pulse Biosciences (PLSE) COO Liane Rae Teplitsky acquiring $99K. United States Antimony (UAMY) CEO Gary C. Evans bought $98K in shares, while Battalion Oil (BATL) director William D. Rogers purchased $91K. On the sell side, Life Time Group (LTH) insiders sold $126M, Relay Therapeutics (RLAY) 10%
AUG 28·SEC EDGAR
SVF Pauling (Cayman) Ltd sold $116.4M of RLAY (indirect holdings)
SVF Pauling (Cayman) Ltd sold 6,000,000 indirectly-held shares of Relay Therapeutics, Inc. (RLAY) at $19.40 ($116.40M total) on 2026-08-25. Filed jointly with SOFTBANK VISION FUND (AIV M2) L.P. (10% owner) and SB INVESTMENT ADVISERS (UK) LTD (10% owner).
RLAY sentiment & insider activity
Recent RLAY coverage spans insider activity, financial news and market movers.
In the last 30 days, RLAY insiders filed 5 SEC Form 4 transactions — no purchases and 5 sales ($117.9M). The most active reporter was Rahmer Peter, See remarks, with 1 filing. 80% of those filings were made under pre-arranged Rule 10b5-1 plans.
What's driving RLAY
Insider sell by the CEO may signal reduced confidence, potentially pressuring the stock short term.
Heavy insider sell likely to weigh on stock.
Large insider sell may pressure RLAY price; indicates possible insider concern.
No material news; likely no immediate price impact.
This is a routine insider sale under a 10b5-1 plan, so it is unlikely to signal new fundamental deterioration by itself.
AlphAI scores every news story that mentions RLAY with an AI model for sentiment and relevance, and aggregates insider trades from Relay Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
News on $RLAY
Score
Patel Sanjiv sold $913K of RLAY
Patel Sanjiv (President and CEO) sold 48,199 shares of Relay Therapeutics, Inc. (RLAY) at $18.94 ($0.91M total) on 2026-09-08 under a Rule 10b5-1 trading plan.
1 min readTop insider buys and sells from Friday’s market activity
On August 28, 2026, notable insider trading included Optimum Communications (OPTU) director Neil S. Subin buying $2.45M in shares, REGENXBIO (RGNX) director Gregory Austin Ciongoli purchasing $949K, and Pulse Biosciences (PLSE) COO Liane Rae Teplitsky acquiring $99K. United States Antimony (UAMY) CEO Gary C. Evans bought $98K in shares, while Battalion Oil (BATL) director William D. Rogers purchased $91K. On the sell side, Life Time Group (LTH) insiders sold $126M, Relay Therapeutics (RLAY) 10%
3 min readSVF Pauling (Cayman) Ltd sold $116.4M of RLAY (indirect holdings)
SVF Pauling (Cayman) Ltd sold 6,000,000 indirectly-held shares of Relay Therapeutics, Inc. (RLAY) at $19.40 ($116.40M total) on 2026-08-25. Filed jointly with SOFTBANK VISION FUND (AIV M2) L.P. (10% owner) and SB INVESTMENT ADVISERS (UK) LTD (10% owner).
1 min read
Relay Therapeutics (RLAY) Reported Q2 Results, Is The Premium P B Multiple Justified?
Relay Therapeutics (RLAY) reported Q2 results, prompting analysis of its premium P/B multiple. The article highlights 3 key rewards and 2 warning signs for investors to consider. It also suggests diversifying research beyond RLAY and offers strategies for identifying undervalued stocks, reliable dividend payers, and resilient companies.
2 min readPatel Sanjiv sold $980K of RLAY
Patel Sanjiv (President and CEO) sold 48,199 shares of Relay Therapeutics, Inc. (RLAY) at $20.33 ($0.98M total) on 2026-08-17 under a Rule 10b5-1 trading plan.
2 min read
Relay Therapeutics Stock Is Up Nearly 500% Over the Past Year
Barchart reports Relay Therapeutics (RLAY) has risen about 486% over the past 52 weeks and is near a new 3-year high, with Barchart giving a 100% “Buy” opinion and a Trend Seeker “Buy” signal. The article cites $4.4B market cap and expects revenue to fall 31.21% this year before rising next year.
5 min readRelay Therapeutics, Inc. (RLAY): Results of Operations and Financial Condition
Relay Therapeutics, Inc. (RLAY) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 AMENDMENT NO. 1 TO THE COMMON STOCK SALES AGREEMENT August 6, 2026 TD Securities (USA) LLC 1 Vanderbilt Avenue New York, New York 10017 Ladies and Gentlemen: This Amendment No. 1 to the Sales Agreement, dated as of August 6, 2026, is entered into by and between Relay
6 min readReturns Matter: NUTX +214%, CORT +145%, GKOS +97% - Were These Biotech Stocks In Your Portfolio?
The article profiles five biotech/healthcare stocks and cites recent catalysts and upcoming events. Glaukos (GKOS) highlights Epioxa launch and raised 2026 sales guidance ahead of Q2 2026 results July 29, 2026. TG Therapeutics (TGTX) cites BRIUMVI trial updates and Q2 results early August. Corcept (CORT) points to Lifyorli progress and raised guidance. Relay (RLAY) and Nutex Health (NUTX) note Phase 3 and upcoming quarterly results. It lists large post-publication price gains for each.
7 min readPatel Sanjiv sold $944K of RLAY
Patel Sanjiv (President and CEO) sold 48,199 shares of Relay Therapeutics, Inc. (RLAY) at $19.58 ($0.94M total) on 2026-07-07 under a Rule 10b5-1 trading plan.
2 min readRahmer Peter sold $954K of RLAY
Rahmer Peter (See remarks) sold 50,000 shares of Relay Therapeutics, Inc. (RLAY) at $19.09 ($0.95M total) on 2026-06-30 under a Rule 10b5-1 trading plan.
1 min read